新诺威：控股子公司SYS6036注射液药物临床试验获批准

Group 1 - The core point of the article is that XinNuoWei's subsidiary, Shiyao Group Jushi Biopharmaceutical Co., has received approval from the National Medical Products Administration for the clinical trial of SYS6036 injection, a humanized monoclonal antibody for tumor immunotherapy [1] - SYS6036 injection is classified under Category 3.3 of therapeutic biological products and is expected to be used for treating various tumors including melanoma, non-small cell lung cancer, esophageal cancer, and head and neck squamous cell carcinoma [1]